SYRE — Spyre Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Spyre Therapeutics Appoints Mark Mckenna To Its Board Of Directors
Brief: Spyre Therapeutics Says Co Got Approval From Nasdaq Staff To Transfer Listing Of Common Stock From Nasdaq Capital Market To Nasdaq Global Select Market
Brief: Peter Harwin Reports 2.32% Stake In Spyre Therapeutics As Of Dec 29 Versus Previous Stake Of 10.59% As Of Dec 7
Brief: Aeglea Biotherapeutics Announces Name Change To Spyre Therapeutics
Brief: Aeglea BioTherapeutics Q3 basic EPS USD -9.34
Aeglea Bio Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview
Brief: Aeglea Bio Therapeutics Inc Received Notice Of Delisting From Nasdaq
Brief: Aeglea Biotherapeutics Announces Reverse Stock Split
U.S. STOCKS ON THE MOVE-Oracle Corp, Aeglea BioTherapeutics, Insmed
Aeglea BioTherapeutics names new finance chief; shares rise
Brief: Aeglea Bio Therapeutics Expands Executive Leadership Team With Appointment Of Industry Veterans Scott Burrows And Heidy Abreu King-Jones
Aeglea Bio Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aeglea Bio Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Aeglea Biotherapeutics Announces Sale Of Pegzilarginase To Immedica Pharma
Brief: Aeglea Bio Therapeutics To Transfer Listing From Nasdaq Global Market To Nasdaq Capital Market
U.S. STOCKS ON THE MOVE-Mosaic, Eli Lilly, I-Mab
U.S. STOCKS ON THE MOVE-Cidara Therapeutics, Crown Crafts, iRobot
Aeglea Bio soars on buyout of biotech Spyre Therapeutics
Brief: Aeglea BioTherapeutics Announces Acquisition Of Spyre Therapeutics